PODNL1 Inhibitors
Chemical inhibitors of PODNL1 can exert their effects through various molecular pathways by targeting specific enzymes and kinases involved in its regulation. Wortmannin and LY294002 are inhibitors that directly target the phosphoinositide 3-kinases (PI3K), which are upstream regulators in the signaling cascade that leads to the activation of PODNL1. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of PODNL1, thereby reducing its activity within the cell. SB203580 operates by selectively inhibiting p38 MAP kinase, another molecule in the signaling pathways that affect PODNL1 activity. By disrupting p38 MAP kinase's function, SB203580 can decrease the signaling that contributes to the functional state of PODNL1.
Similarly, the compound SP600125 inhibits the c-Jun N-terminal kinase (JNK) signaling pathway, which can regulate proteins that share functional similarities with PODNL1. By blocking JNK, SP600125 can decrease PODNL1 activity. PD98059 and U0126 both target the mitogen-activated protein kinase kinase (MEK), with PD98059 inhibiting MEK1 and U0126 inhibiting both MEK1 and MEK2. The inhibition of MEK leads to a reduction in extracellular signal-regulated kinase (ERK) pathway activity, which is potentially involved in the regulation of PODNL1. PP2 and Dasatinib, on the other hand, are inhibitors of the Src family tyrosine kinases, which can influence various signaling pathways including those involving PODNL1. By inhibiting these kinases, both PP2 and Dasatinib can reduce PODNL1's functional activity. BIBF 1120, or Nintedanib, targets multiple receptor tyrosine kinases such as VEGFR, PDGFR, and FGFR, which can modulate pathways that regulate PODNL1, leading to decreased activity of the protein. Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK), part of the Rho/ROCK pathway that intersects with PODNL1 signaling pathways, and thus its inhibition also results in reduced PODNL1 activity. Lastly, KN-93 and Go6983 inhibit calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C (PKC) respectively, both of which are involved in signaling cascades that may regulate PODNL1 function, and their inhibition can lead to a decrease in the activity of PODNL1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi that inhibits phosphoinositide 3-kinases (PI3K). Since PODNL1 signaling is known to be influenced by the PI3K/Akt pathway, inhibition of PI3K by Wortmannin can lead to reduced PODNL1 activity by preventing its phosphorylation and activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, and by inhibiting this kinase, it would lead to decreased activation of downstream targets, including those that mediate the function of PODNL1, thereby inhibiting the protein's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that selectively inhibits p38 MAP kinase. Inhibition of p38 MAP kinase can disrupt the signaling pathways that contribute to the functional activation of PODNL1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which can inhibit the JNK signaling pathway. Since JNK pathway can regulate proteins similar to PODNL1, its inhibition can decrease the functional activity of PODNL1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which prevents the activation of extracellular signal-regulated kinase (ERK) pathway. Since the ERK pathway can be involved in the regulation of proteins like PODNL1, its inhibition by PD98059 can reduce PODNL1 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. By inhibiting MEK activity, U0126 prevents the activation of ERK, which could lead to decreased regulation of proteins like PODNL1 and a consequent reduction in its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can influence various signaling cascades that may involve PODNL1, and inhibition by PP2 can decrease the functional activity of PODNL1 through these pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted inhibitor, but it has known activity against Src family kinases. Since Src kinases can regulate pathways that involve PODNL1, Dasatinib can inhibit the functional activity of PODNL1 by inhibiting these kinases. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
BIBF 1120, also known as Nintedanib, is an inhibitor that targets multiple receptor tyrosine kinases including VEGFR, PDGFR, and FGFR. As these receptors can regulate pathways involving PODNL1, their inhibition by BIBF 1120 can lead to decreased PODNL1 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which is part of the Rho/ROCK pathway that could intersect with signaling pathways involving PODNL1. Inhibition of ROCK by Y-27632 can lead to reduced PODNL1 activity. | ||||||